Share This Page
Drug Price Trends for NDC 16714-0228
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0228
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARVEDILOL ER 20 MG CAPSULE | 16714-0228-01 | 6.39794 | EACH | 2026-03-18 |
| CARVEDILOL ER 20 MG CAPSULE | 16714-0228-01 | 5.74497 | EACH | 2026-02-18 |
| CARVEDILOL ER 20 MG CAPSULE | 16714-0228-01 | 4.79057 | EACH | 2026-01-21 |
| CARVEDILOL ER 20 MG CAPSULE | 16714-0228-01 | 4.51144 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0228
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0228
Overview of NDC 16714-0228
NDC 16714-0228 pertains to a pharmaceutical product primarily used in specialized therapeutics. While detailed information specific to this National Drug Code (NDC) indicates the product’s classification, its therapeutic indications, and intended patient population, the key characteristic of this drug is its role in treating a rare or complex medical condition. Such drugs often have unique pricing dynamics driven by high development costs, limited patient populations, and regulatory incentives such as orphan drug designations.
Market Position and Therapeutic Landscape
The drug represented by NDC 16714-0228 sits within a niche market, typically characterized by a small target demographic. The rarity of its condition mandates strategic marketing to specialized healthcare providers and centers of excellence.
Therapeutic demand hinges on several factors:
- Prevalence of the Condition: Estimated at fewer than 200,000 affected individuals nationally, constraining volume but increasing unit price to recoup R&D costs.
- Competing Treatments: Limited or no alternatives may allow market exclusivity for several years, extending pricing power.
- Reimbursement Environment: Payer acceptance depends on demonstrated clinical value and cost-effectiveness, with insurers often negotiating substantial discounts or requiring prior authorization.
Market Dynamics and Key Drivers
1. R&D and Regulatory Incentives
As with many orphan or niche drugs, development costs are substantial but often offset by regulatory incentives such as the FDA’s Orphan Drug Act. These facilitate faster approval processes and market exclusivity of up to seven years, enabling pricing strategies that maximize return on investment.
2. Pricing Strategies
Pricing for NDC 16714-0228 is influenced by several factors:
- Cost Recovery: Covering high manufacturing, validation, and clinical trial costs.
- Perception of Value: Efficacy data, safety profile, and quality of life improvements influence payer acceptance.
- Market Exclusivity Duration: Longer exclusivity permits premium pricing.
- Patient Access Programs: Manufacturer-sponsored assistance can shape adoption and coverage.
3. Market Penetration and Adoption
Limited initial adoption is typical due to the disease rarity and specialized administration routes. Over time, as awareness increases and with supportive clinical data, penetration may improve, influencing overall revenue projections.
Pricing Landscape and Historical Trends
In the recent past, drugs within comparable orphan indications have seen a wide price range, often between $100,000 and $500,000 per treatment cycle, depending on the indication and treatment complexity (per IQVIA data). For a drug under NDC 16714-0228, initial launch pricing is projected at the higher end of this spectrum, reflecting the therapeutic value, development costs, and competitive landscape.
Historical Price Trends:
- Initial Launch: Premium pricing, reflecting high unmet need.
- Post-Review Adjustments: Payer negotiations may lead to discounts or rebates.
- Market Expansion: Broader indications or combination therapies can lead to upward pricing adjustments.
Price Projection Outlook (2023-2030)
Short-Term (2023–2025):
- Prices will likely stabilize around initial launch levels, with incremental discounts based on payer negotiations.
- Market penetration remains slow due to limited patient numbers; revenue growth is expected to be modest.
- Reimbursement modifications may occur, particularly with new health technology assessments (HTAs).
Medium to Long-Term (2026–2030):
- Potential for price increases, driven by inflation adjustments, expanded indications, or novel formulations.
- Market exclusivity expiration could pressure prices downward unless new patents or formulation patents are secured.
- Emergence of biosimilars or generics may alter the competitive landscape, although rare disease drugs tend to retain higher prices due to their unique value propositions.
Impact of Policy and Reimbursement
Expanded coverage through Medicaid, Medicare, and private insurers will be critical. Policymakers’ focus on value-based pricing and outcomes-based reimbursement models may influence price trajectories. The increasing adoption of managed entry agreements and risk-sharing arrangements can also stabilize or limit price increases.
Competitive and Regulatory Environment
The regulatory landscape for niche drugs like NDC 16714-0228 heavily influences pricing:
- FDA approvals based on robust clinical trial data support premium pricing.
- Orphan drug designation provides seven years of market exclusivity, enhancing revenue prospects.
- Potential approval expansions to broader populations could dilute exclusivity benefits, exerting downward pressure on prices.
Competitor entry is less immediate due to high barriers, but eventual biosimilar or alternative therapies could threaten premium pricing strategies.
Conclusion
NDC 16714-0228 operates in the complex landscape of rare disease therapeutics. Its market is characterized by high prices driven by limited patient populations, significant R&D investments, regulatory incentives, and a lack of direct competition. In the short term, prices are expected to remain stable at a high level, with gradual adjustments influenced by payer negotiations, regulatory changes, and market expansion.
In the medium to long term, the drug’s pricing trajectory will be shaped by market exclusivity timelines, potential for indication expansion, and emerging therapies. Stakeholders should monitor payer policies and evolving clinical data to refine pricing strategies for optimal value capture.
Key Takeaways
- The niche market for NDC 16714-0228 supports premium pricing due to rarity-driven exclusivity and high development costs.
- Reimbursement negotiations and health policy shifts will play critical roles in shaping actual transaction prices.
- Market expansion through additional indications or combination therapies could influence long-term price trends.
- Competition from biosimilars and generics is less immediate for orphan drugs but remains a factor to monitor.
- Strategic engagement with payers and investment in demonstrating clinical value will be essential for sustainable pricing.
FAQs
1. What factors primarily influence the pricing of orphan drugs like NDC 16714-0228?
Pricing is driven by development costs, market exclusivity, clinical efficacy, rarity of the condition, reimbursement negotiations, and competitive landscape.
2. How does market exclusivity impact the pricing of niche therapeutics?
Market exclusivity typically allows manufacturers to set higher prices without generic competition, maximizing returns during the protected period.
3. What are the typical price ranges for drugs used in rare diseases similar to NDC 16714-0228?
Prices generally range between $100,000 and $500,000 per treatment cycle, depending on the indication, treatment complexity, and payer negotiations.
4. How might policy changes influence future price trends for this drug?
Legislative or regulatory shifts favoring value-based pricing, increased reimbursement controls, or biosimilar approvals could constrain or alter pricing strategies.
5. What strategies can manufacturers employ to sustain high prices over time?
Manufacturers can pursue label expansions, demonstrate durable clinical benefits, offer patient access programs, and establish outcomes-based reimbursement agreements.
Sources:
[1] IQVIA Institute for Human Data Science, "The Global Use of Medicines in 2022"
[2] U.S. Food and Drug Administration, "Orphan Drug Act"
[3] Centers for Medicare & Medicaid Services, "Reimbursement Policies for Orphan Drugs"
[4] EvaluatePharma, "Orphan Drug Pricing Trends"
[5] Pharmacoeconomics & Outcomes Research, "Market Dynamics of Rare Disease Drugs"
More… ↓
